Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 3;9(51):29565–29573. doi: 10.18632/oncotarget.25619

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2018 Chteinberg et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Dose-response curves of the MCPyV-positive MKL-1, MKL-2, WaGa, PeTa (A and C), and MCPyV-negative MCC13, MCC26, REH and U266 (B and D) cell lines after 120 h treatment with varying molar concentrations [M] of idelalisib and BYL719. The cell viability is inhibited by idelalisib or BYL719 in all cell lines in a dose-dependent manner. IC₅₀ were calculated from 3 independent (n = 3) experiments with eight replicates each. Bars symbolize the standard deviation of the mean. The overall p values of all dose response curves besided the treatment of U266 are < 0.001.